Liquidia Corporation
LQDA
Ранг среди акций
#4685
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Цена акции
$36.17
Рыночная капитализация
$3.24B
Изменение (1 день)
5.98%
Изменение (1 год)
48.00%
Страна
US
Торговля Liquidia Corporation (LQDA)
Категория
Healthcare
Коэффициент P/S для Liquidia Corporation (LQDA)
Коэффициент P/S на October 2026 TTM: 6.74
Согласно последним финансовым отчетам и цене акций Liquidia Corporation, текущий коэффициент P/S (TTM) составляет 6.74. В конце 2023 он составлял 44.71.
История P/S для Liquidia Corporation с 2016 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 124.46% |
US
|
